Bezlotoxumab denied for failing step therapy by Aetna?

Aetna's specific coverage criteria for bezlotoxumab are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Bezlotoxumab for Step Therapy

Aetna's step-therapy denial means the plan requires documentation that specific prior treatments were tried and found to be inadequate before bezlotoxumab will be authorized. For Clostridioides difficile recurrence prevention, step-therapy requirements typically reflect an expectation that standard antibiotic management was attempted first, and that bezlotoxumab is being added because of documented inadequacy or elevated recurrence risk rather than as a first-line choice. Because bezlotoxumab is not an antibiotic and works through a different mechanism, the step-therapy framing can be clinically awkward — but meeting the documentation standard is usually achievable.

## Why This Denial Is Appealable

Step-therapy denials are routinely overturned when the medical record contains explicit documentation of prior antibiotic treatment with dates and outcomes. Most step-therapy requirements can also be bypassed when a prescriber documents clinical contraindication to a required step or provides medical justification for skipping a step — many states have enacted step-therapy exception laws that apply to state-regulated plans. Even for ERISA-governed plans, a prescriber's well-reasoned medical-necessity argument carries significant weight with an independent reviewer.

## Federal Appeal Framework

• Step-therapy exception request: Many plans offer a formal exception process before or alongside the appeal. Check Aetna's member handbook for this pathway.
• Internal appeal (ERISA §503 / ACA): File within the deadline stated on the denial notice.
• State step-therapy protections: If your plan is state-regulated (non-ERISA), check whether your state has enacted step-therapy exception legislation — many require insurers to grant exceptions for clinical contraindication or prior treatment failure.
• External review (ACA §2719): After the final internal denial, an IRO reviews the case. Window is approximately four months from the final internal denial.
• Expedited track: Available with prescriber certification of urgent medical need.

## Concrete Appeal Steps

1. Request Aetna's step-therapy protocol for bezlotoxumab — identify exactly which prior-treatment steps are required. 2. Review the patient's chart for documentation of each required step, including dates, agents used, and outcomes. 3. For any required step not yet attempted, have the prescriber provide a written clinical reason why it was skipped or is clinically inappropriate. 4. Obtain the FDA-approved prescribing label (Zinplava) to confirm the indication context that supports medical necessity. 5. File the appeal or exception request with a prescriber letter and complete treatment history.

## Documentation to Gather

• Prior *C. difficile* treatment history: Every antibiotic course used for prior episodes, with agent names, dates, and documented outcomes (response, recurrence, adverse effect).
• Current episode documentation: Laboratory confirmation, clinical presentation, and timing relative to prior treatment.
• Recurrence risk-factor documentation: Chart evidence of any clinically relevant risk factors per the FDA label's indicated population.
• Prescriber step-therapy exception letter: Addressing each required step — confirming completion with outcome, or explaining clinical rationale for exception — with specific chart citations.

## Criteria-Mapping Structure

List each step required by Aetna's protocol in a table. For each step: (1) confirm it was completed and provide the chart date and outcome, or (2) state the prescriber's clinical reason for exception with the supporting chart reference. Attach the FDA label indication language to confirm the overall treatment context. A complete step-by-step accounting — rather than a general narrative — is the format most likely to result in a favorable determination.